Please ensure Javascript is enabled for purposes of website accessibility

Why 22nd Century Group Stock Briefly Spiked Monday

By George Budwell - Oct 17, 2017 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

22nd Century Group may be ready to take flight as a result of the FDA's latest tobacco harm reduction initiative.

What happened

Shares of 22nd Century Group (XXII -5.84%), a plant biotech company focusing on the development of low nicotine cigarettes and smoking cessation aids, jumped by as much as 10.7% yesterday before ultimately ending the day up 2.14%. This brief double-digit rally was sparked by a new 12-month price target from Chardan Capital Markets analyst James McIlree. 

So what

What really appears to have caught investors' eye yesterday, however, was the magnitude of the price target increase. Specifically, Mcllree's new price target of $11.50 (up from $3.50) implies an upside potential of a whopping 310% compared to where the stock opened on Monday. 

Cigarettes laid out on top of a pile of $100 bills.

Image source: Getty Images.

Now what

Although Mcllree's revised outlook was light on specifics, his central thesis appears to revolve around the latest tobacco harm reduction initiative from the U.S. Food and Drug Administration, or FDA. In short, 22nd Century Group's low nicotine cigarette platform may end up benefiting immensely from the FDA's new mandate, under the Family Smoking Prevention and Tobacco Control Act, calling for all combustible cigarettes sold in the United States to contain nicotine levels that are nonaddictive. 

While 22nd Century Group does appear to be getting into the low nicotine cigarette game at almost the perfect time, there are still some good reasons to remain cautious with this speculative biotech stock right now. Big tobacco's ginormous lobbying machine, after all, could ultimately blunt the FDA's plans, and that would spell disaster for companies like 22nd Century Group that are counting on this latest regulatory overhaul to spur revenue growth in the years ahead. Thus, this promising small-cap biotech arguably isn't well suited for investors that are adverse to risk -- despite its tremendous upside potential. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

22nd Century Group, Inc. Stock Quote
22nd Century Group, Inc.
$2.42 (-5.84%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.